Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

H. Quach; D. Joshua; J. Ho; J. Szer; A. Spencer; S. Harrison; P. Mollee; A. Roberts; N. Horvath; D. Talaulikar; B. To; A. Zannettino; R. Brown; L. Catley; B. Augustson; W. Jaksic; J. Gibson; H. M. Prince

doi:10.1111/imj.12688

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

H. Quach, D. Joshua, J. Ho, J. Szer, A. Spencer, S. Harrison, P. Mollee, A. Roberts, N. Horvath, D. Talaulikar, B. To, A. Zannettino, R. Brown, L. Catley, B. Augustson, W. Jaksic, J. Gibson, H. M. Prince

Blood Cancer Program

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

Original language	English
Pages (from-to)	335-343
Number of pages	9
Journal	Internal Medicine Journal
Volume	45
Issue number	3
DOIs	https://doi.org/10.1111/imj.12688
Publication status	Published or Issued - 1 Mar 2015

Keywords

Elderly
Multiple myeloma
Therapy
Transplant ineligible

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1111/imj.12688

Cite this

Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talaulikar, D., To, B., Zannettino, A., Brown, R., Catley, L., Augustson, B., Jaksic, W., Gibson, J., & Prince, H. M. (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(3), 335-343. https://doi.org/10.1111/imj.12688

@article{68bd24b969354fbc9e4bee16df0165f0,

title = "Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group",

abstract = "Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.",

keywords = "Elderly, Multiple myeloma, Therapy, Transplant ineligible",

author = "H. Quach and D. Joshua and J. Ho and J. Szer and A. Spencer and S. Harrison and P. Mollee and A. Roberts and N. Horvath and D. Talaulikar and B. To and A. Zannettino and R. Brown and L. Catley and B. Augustson and W. Jaksic and J. Gibson and Prince, {H. M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Royal Australasian College of Physicians.",

year = "2015",

month = mar,

day = "1",

doi = "10.1111/imj.12688",

language = "English",

volume = "45",

pages = "335--343",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "3",

}

Quach, H, Joshua, D, Ho, J, Szer, J, Spencer, A, Harrison, S, Mollee, P, Roberts, A, Horvath, N, Talaulikar, D, To, B, Zannettino, A, Brown, R, Catley, L, Augustson, B, Jaksic, W, Gibson, J & Prince, HM 2015, 'Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 3, pp. 335-343. https://doi.org/10.1111/imj.12688

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. / Quach, H.; Joshua, D.; Ho, J. et al.
In: Internal Medicine Journal, Vol. 45, No. 3, 01.03.2015, p. 335-343.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation

T2 - Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

AU - Quach, H.

AU - Joshua, D.

AU - Ho, J.

AU - Szer, J.

AU - Spencer, A.

AU - Harrison, S.

AU - Mollee, P.

AU - Roberts, A.

AU - Horvath, N.

AU - Talaulikar, D.

AU - To, B.

AU - Zannettino, A.

AU - Brown, R.

AU - Catley, L.

AU - Augustson, B.

AU - Jaksic, W.

AU - Gibson, J.

AU - Prince, H. M.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

AB - Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.

KW - Elderly

KW - Multiple myeloma

KW - Therapy

KW - Transplant ineligible

UR - http://www.scopus.com/inward/record.url?scp=84923823289&partnerID=8YFLogxK

U2 - 10.1111/imj.12688

DO - 10.1111/imj.12688

M3 - Article

C2 - 25735577

AN - SCOPUS:84923823289

SN - 1444-0903

VL - 45

SP - 335

EP - 343

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 3

ER -

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this